If I had $10,000 to put to work in ASX 200 shares this February, I wouldn't overthink it. I'd focus on a small group of high-quality businesses with strong earnings, clear long-term drivers, and the ability to ride out whatever the market throws at them this year.
This isn't about finding the next hot stock. It's about stacking the odds in favour of sensible, long-term returns.
Here's where my money would go.
Image source: Getty Images
CSL Ltd (ASX: CSL)
After a difficult period marked by slower plasma margin recovery, softer albumin demand in China, and weakness in influenza vaccines, expectations around CSL are far more realistic than they were a few years ago. What hasn't changed is the quality of the business.
CSL remains a global leader in plasma therapies, operating in an oligopolistic market with very high barriers to entry. Demand for immunoglobulins continues to grow structurally, and efficiency initiatives should support margins over time. For a long-term investor, I think the risk-reward looks far more balanced than it did near the top of the cycle.
ResMed Inc (ASX: RMD)
ResMed is another ASX 200 name I'd be very comfortable buying with the $10,000. The medical device company continues to deliver strong revenue growth, improving margins, and expanding cash flow, driven by rising awareness and diagnosis of sleep apnoea globally. Its software and digital health ecosystem also adds a layer of recurring revenue that many other companies lack.
ResMed doesn't need a perfect economic backdrop to grow. Its products address chronic conditions, which gives earnings a degree of defensiveness alongside genuine long-term growth.
Wesfarmers Ltd (ASX: WES)
I see Wesfarmers as a capital allocation story. Bunnings and Kmart generate strong cash flows, which management can reinvest into new growth areas or return to shareholders. Over time, that discipline tends to compound quietly.
It's not a stock that will double overnight. But as part of a $10,000 portfolio, this ASX 200 share offers stability, optionality, and a history of sensible decision-making.
Goodman Group (ASX: GMG)
Goodman Group gives exposure to a different growth theme altogether. It sits at the heart of logistics, urban infill, and data centre infrastructure. Demand for high-quality industrial space remains strong, and its development pipeline continues to grow alongside global data and e-commerce needs.
While interest rates and valuations can create short-term noise, the long-term demand for the assets that this ASX 200 share builds and owns looks very robust to me.
HUB24 Ltd (ASX: HUB)
HUB24 continues to take market share in the Australian wealth platform space, supported by strong adviser adoption and rising funds under administration. Its platform model provides operating leverage, which means earnings can grow faster than revenue as scale increases.
It's not the cheapest share on the ASX 200, but high-quality platform businesses rarely are. What matters is execution, and HUB24 has been delivering consistently. This is evident in its recent quarterly update.
Foolish takeaway
If I were investing $10,000 in ASX 200 shares this February, I'd spread it across a mix of global leaders, structural growers, and dependable compounders.
Each of my picks in this article brings something different to the table. But together, they create a portfolio that I think could hold up well in the short term and compound nicely over the long run.
